Dr. Irshad’s TakeHyperhidrosis Surgery

Who is a good candidate
Focal pattern of sweating
Early onset
Meaningful impact on life
Non-surgical options tried
Selection principles informed by published surgical consensus and diagnostic criteria.1,3,9
Who is not a good candidate
Night-time (nocturnal) sweating
Facial / cranial-only sweating
Whole-body or truncal sweating
Late-life or perimenopausal onset
BMI over 30
Poorly controlled thyroid disease
Unmanaged anxiety, depression, PTSD or ADHD
Surgical technique & nerve levels
Palms (palmar)R3–R4
Underarms (axillary)R4–R5
Nerve of Kuntz~R2–R3
On the dayDay surgery
Side effects & what to expect
Compensatory sweating
Phantom sweating
Early sweat bursts
Gustatory sweating
Lower resting heart rate
Post-thoracoscopy discomfort
Horner’s syndrome
In my words
Why this works for focal hyperhidrosis
Primary focal hyperhidrosis — heavy, localized sweating of the palms, underarms or feet that usually starts young and can run in families — is driven by over-active signalling along the sympathetic nerve chain in the chest. Non-surgical treatments can help, but they are temporary and the sweating is often refractory to them over time. ETS interrupts that signal at its source, which is why the result is immediate and, for the right patient, long-lasting.5 In short, it treats the cause rather than the symptom — the reason a carefully chosen patient sees an improvement that is both instant and durable.
Clipping vs. cutting the nerve: my view
Patients often ask whether the nerve can be clipped rather than divided. Clipping places a small titanium clip across the chain (R3 for palmar, R4 for axillary), sometimes offered on the premise it can be removed if side effects prove troublesome. In my experience that reversibility is largely theoretical — once a clip has been in place three to four months I regard the effect as essentially permanent — the nerve undergoes irreversible (Wallerian) degeneration.8 Presenting clipping as an easy “undo” can create a false sense of security and weaken the careful patient selection that matters most. My philosophy is the reverse: choose the right patient so carefully that reversal is never wanted. Clipping remains reasonable for some patients, but only with very close follow-up and readiness to remove the clips within weeks, not months.
The evidence, briefly
- Cerfolio RJ, De Campos JRM, Bryant AS, et al. The Society of Thoracic Surgeons Expert Consensus for the Surgical Treatment of Hyperhidrosis. Ann Thorac Surg. 2011;91(5):1642–1648.
- Menna C, Ibrahim M, Andreetti C, et al. Long-term compensatory sweating results after sympathectomy for palmar and axillary hyperhidrosis. Ann Cardiothorac Surg. 2016;5(1):26–32.
- Hornberger J, Grimes K, Naumann M, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol. 2004;51(2):274–286.
- Ramsaroop L, Partab P, Singh B, Satyapal KS. Thoracic origin of a sympathetic supply to the upper limb: the ‘nerve of Kuntz’ revisited. J Anat. 2001;199(Pt 6):675–682.
- Martínez-Hernández NJ, Estors-Guerrero M, Galbis-Caravajal JM, et al. Endoscopic thoracic sympathectomy for primary hyperhidrosis: an over a decade-long follow-up on efficacy, impact, and patient satisfaction. J Thorac Dis. 2024;16(12):8292–8299.
- Henning MAS, Barati F, Jemec GBE. Quality of life in individuals with primary hyperhidrosis: a systematic review and meta-analysis. Clin Auton Res. 2023;33(5):519–528.
- Lee SS, Lee YU, Lee JH, Lee JC. Comparison of the long-term results of R3 and R4 sympathicotomy for palmar hyperhidrosis. Korean J Thorac Cardiovasc Surg. 2017;50(3):197–201.
- Loscertales J, Congregado M, Jimenez-Merchán R, et al. Sympathetic chain clipping for hyperhidrosis is not a reversible procedure. Surg Endosc. 2012;26(5):1258–1263.
- Hamm H, Naumann MK, Kowalski JW, Kütt S, Kozma C, Teale C. Primary focal hyperhidrosis: disease characteristics and functional impairment. Dermatology. 2006;212(4):343–353.
- Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ. 2001;323(7313):596.